MedTrace Logo

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

NCT06808477 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 237

Last updated 2026-08-13

No results posted yet for this study

Summary

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Conditions

Interventions

DRUG

BBT001

BBT001 will be administered

DRUG

Placebo

Placebo will be administered

Sponsors & Collaborators

  • Bambusa Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lisa Li · Bambusa Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-27
Primary Completion
2027-02-28
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06808477 on ClinicalTrials.gov